Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LavipharmATH:LAVI +1.11%82 FCF Yield % is 0.74 as of Aug. 05, 2026, which is 77% below its 10-year median of 3.17. GuruFocus rates ATH:LAVI with a GF Score™ of 82/100 and a GF Value™ of €1.19 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Lavipharm ranks better than 50.15% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Lavipharm FCF Yield % Related Terms
Lavipharm FCF Yield % Historical Data
* Premium members only.
The historical data trend for Lavipharm's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATH:LAVI vs ZTS, UTHR, VTRS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lavipharm FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lavipharm's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Lavipharm's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lavipharm (ATH:LAVI) has a FCF Yield % of 0.74 as of Aug. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lavipharm and its competitors. This is 77% below median its historical median of 3.17. According to the industry distribution chart, Lavipharm ranks #502 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 49.9%.
Is Lavipharm's FCF Yield % too high?
Lavipharm's current FCF Yield % of 0.74 is 77% below median its 10-year median of 3.17. The Drug Manufacturers industry median FCF Yield % is 0.73. Lavipharm's value of 0.74 is 1.4% above this industry median. Based on the distribution chart, Lavipharm ranks #502 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lavipharm has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lavipharm's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lavipharm ranks #502 out of 1007 companies for FCF Yield %. This puts Lavipharm in the upper half of its industry. The industry median FCF Yield % is 0.73. Lavipharm's value of 0.74 is 1.4% above this benchmark. While the company's 10-year median is 3.17 vs. the industry median of 0.73, Lavipharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.73, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lavipharm's current FCF Yield % of 0.74 is 1.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lavipharm and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lavipharm's current FCF Yield % is 0.74, which is 77% below median its own 10-year median of 3.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lavipharm stock overvalued right now?
Based on GuruFocus' analysis, Lavipharm (ATH:LAVI) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.19, compared to a current price of €1.64 — trading 37.8% above its estimated fair value. The current FCF Yield % is 0.74, which is 77% below median its 10-year median of 3.17 and 1.4% above the Drug Manufacturers industry median of 0.73. Lavipharm's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Lavipharm (ATH:LAVI), the current FCF Yield % is 0.74 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lavipharm (ATH:LAVI) Overvalued in 2026?
Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued.
The current stock price of €1.64 is trading 37.8% above its estimated GF Value™ of €1.19.
GuruFocus considers Lavipharm to be Significantly Overvalued.
Key valuation signals for ATH:LAVI:
FCF Yield %: 0.74 (77% below median its 10-year median of 3.17)
GF Value™: €1.19 vs. price of €1.64 (37.8% above fair value)
Industry Position: 1.4% above the Drug Manufacturers median (#502 of 1007)
No single metric tells the full story. See the ATH:LAVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
82GF Score
Get the complete analysis for ATH:LAVI
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATH:LAVI has been successfully added to your 
